Perspective Therapeutics

Perspective Therapeutics EBIT Margin

The EBIT Margin (Operating Margin) of Perspective Therapeutics (CATX) as of Oct 21, 2026 is -12,846.61 %. In the previous year, EBIT Margin (Operating Margin) was 719.33 % — a change of -1,885.92% (lower).

EBIT Margin

-12,846.61 %

YoY

-1,885.92%

Last updated:

EBIT Margin (Operating Margin) of Perspective Therapeutics is 2025 -12,846.61 % . EBIT Margin (Operating Margin) of Perspective Therapeutics was 2024 719.33 % . It decreases by -1,885.92% lower compared to the previous year.

Perspective Therapeutics's operating (EBIT) margin stands at -12,846.6%, down from -34.2% several years earlier.

The Perspective Therapeutics EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2018
-113.61 USD
Jan 1, 2019
-72.16 USD
Jan 1, 2020
-35.91 USD
Jan 1, 2021
-34.19 USD
Jan 1, 2022
-68.47 USD
Jan 1, 2023
-213.71 USD
Jan 1, 2024
719.33 USD
Jan 1, 2025
-12,846.61 USD
The Perspective Therapeutics EBIT Margin history
YEAREBIT MarginYoY
-12,846.61 %-1,885.92%
719.33 %-436.59%
-213.71 %+212.14%
-68.47 %+100.26%
-34.19 %-4.79%
-35.91 %-50.24%
-72.16 %-36.48%
-113.61 %-14.24%
-132.47 %+24.32%
-106.56 %+13.20%
-94.13 %-13.44%
-108.75 %+11,999.24%
-0.90 %+26.68%
-0.71 %+25.45%
-0.57 %-25.43%
-0.76 %-36.50%
-1.19 %-2.87%
-1.23 %-27.26%
-1.69 %-53.15%
-3.61 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

EBIT Margin (Operating Margin) of Perspective Therapeutics is -12,846.61 % in 2025.

EBIT Margin (Operating Margin) of Perspective Therapeutics changed from 719.33 % to -12,846.61 %, representing a -1,885.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Perspective Therapeutics with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Perspective Therapeutics

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Perspective Therapeutics